CYTOSAR

This brand name is authorized in Croatia, Estonia, Hong Kong SAR China, Mexico, Poland, South Africa.

Active ingredients

The drug CYTOSAR contains one active pharmaceutical ingredient (API):

1	Cytarabine UNII 04079A1RDZ - CYTARABINE
	Cytarabine (ARA-C) is metabolised in vivo to ARA-CTP phosphorylated compound. This competitively inhibits DNA polymerase and may also inhibit certain acid kinase enzymes.
	Read more about Cytarabine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
CYTOSAR Powder for solution for injection	MPI, Generic	Health Products Regulatory Authority (ZA)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01BC01	Cytarabine	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BC Pyrimidine analogues
Discover more medicines within L01BC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1001383, 1001451, 1001530
HK	Department of Health Drug Office	27972, 29543
HR	Agencija za lijekove i medicinske proizvode	HR-H-301692413
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	74316
PL	Rejestru Produktów Leczniczych	100016481, 100016498, 100016506, 100396383, 100396390
ZA	Health Products Regulatory Authority	T/26/47, T/26/48